News & Events
News & Events
Institut Pasteur Korea held the third Research Strategy Advisory Committee meeting
2022-05-10
Institut Pasteur Korea held the third
Research Strategy Advisory Committee meeting
Research Strategy Advisory Committee meeting
On April 28, Institut Pasteur Korea (IPK) held the third Research Strategy Advisory Committee Meeting. The Research Strategy Advisory Committee (hereinafter “RSAC”) aims to discuss with domestic experts in the field of infectious disease and drug development the strategies for strengthening IPK’s R&D network and cooperation. Eight experts* from academia, institutes, and hospitals attended the meeting.
.jpg)
IPK’s 2022 research plans and implementation strategies that shared its key research activities were presented to the Committee. Dr. Inhee Choi, Head of Medicinal Chemistry, introduced ongoing projects targeting therapeutics discovery for tuberculosis, antibiotic resistance, antivirals, and anticancer, which utilized in-house compound library and chembioinformatics technology. Dr. Euiho Kim, Head of the Viral Immunology Lab, shared the team’s collaborative research on analyzing profiles of individuals vaccinated against COVID-19, identification of immunomodulatory compounds, and more. In addition, Dr. Seungtaek Kim, Head of the Zoonotic Virus Lab, introduced the results of joint research for COVID-19 therapeutics development, including an innovative approach of combining virtual and real drug screening, natural product screening, and development of novel chemical compounds. Lastly, Dr. Kyuho Paul Park, Acting Head of the Applied Molecular Virology Lab, explained the progress of developing therapeutic candidates for HBV/HDV coinfection.
The RSAC noted IPK’s excellent research achievements obtained through COVID-19 drug repositioning and encouraged to utilize the institute’s strengths consistently for implementing infectious disease response strategies, such as therapeutics development for post COVID-19. The Committee urged to continuously advance IPK’s research capacity while overcoming the limited budget.
Dr. Youngmee Jee, CEO of IPK, mentioned that the institute has been working to expand technology support services and obtain more research project funding to stabilize the budget and also activated joint research through the Pasteur Network, and initiated discussions with major international funding organizations to diversify funding sources. She further explained that IPK is in the process of establishing a five-year R&D strategic plan encompassing mid-term goals and key milestones. On behalf of the discussions from the meeting, she said that she will put every effort to ensure IPK’s fulfillment of its role as an Asia-Pacific infectious disease research hub and a strategic asset for domestic infectious disease response.
* RSAC members: Prof. Man-Seong Park of Korea University College of Medicine; Dr. Bum Tae Kim, Director of the Center for Convergence Research of Emerging Virus Infection (CEVI) at KRICT; Dr. Joo-sil Lee, Director of GFID; Dr. Choong-Min Ryu, Director of Infectious Disease Research Center at KRIBB; Prof. Seung Bum Park of Seoul National University College of Natural Sciences; Prof. Sung-han Kim of Asan Medical Center Department of Infectious Diseases; Prof. Euicheol Shin of KAIST Graduate School of Medical Science and Engineering; and Dr. Je-kyung Seong, Director of Korea Mouse Phenotyping Center (KMPC).
IPK’s 2022 research plans and implementation strategies that shared its key research activities were presented to the Committee. Dr. Inhee Choi, Head of Medicinal Chemistry, introduced ongoing projects targeting therapeutics discovery for tuberculosis, antibiotic resistance, antivirals, and anticancer, which utilized in-house compound library and chembioinformatics technology. Dr. Euiho Kim, Head of the Viral Immunology Lab, shared the team’s collaborative research on analyzing profiles of individuals vaccinated against COVID-19, identification of immunomodulatory compounds, and more. In addition, Dr. Seungtaek Kim, Head of the Zoonotic Virus Lab, introduced the results of joint research for COVID-19 therapeutics development, including an innovative approach of combining virtual and real drug screening, natural product screening, and development of novel chemical compounds. Lastly, Dr. Kyuho Paul Park, Acting Head of the Applied Molecular Virology Lab, explained the progress of developing therapeutic candidates for HBV/HDV coinfection.
The RSAC noted IPK’s excellent research achievements obtained through COVID-19 drug repositioning and encouraged to utilize the institute’s strengths consistently for implementing infectious disease response strategies, such as therapeutics development for post COVID-19. The Committee urged to continuously advance IPK’s research capacity while overcoming the limited budget.
Dr. Youngmee Jee, CEO of IPK, mentioned that the institute has been working to expand technology support services and obtain more research project funding to stabilize the budget and also activated joint research through the Pasteur Network, and initiated discussions with major international funding organizations to diversify funding sources. She further explained that IPK is in the process of establishing a five-year R&D strategic plan encompassing mid-term goals and key milestones. On behalf of the discussions from the meeting, she said that she will put every effort to ensure IPK’s fulfillment of its role as an Asia-Pacific infectious disease research hub and a strategic asset for domestic infectious disease response.
* RSAC members: Prof. Man-Seong Park of Korea University College of Medicine; Dr. Bum Tae Kim, Director of the Center for Convergence Research of Emerging Virus Infection (CEVI) at KRICT; Dr. Joo-sil Lee, Director of GFID; Dr. Choong-Min Ryu, Director of Infectious Disease Research Center at KRIBB; Prof. Seung Bum Park of Seoul National University College of Natural Sciences; Prof. Sung-han Kim of Asan Medical Center Department of Infectious Diseases; Prof. Euicheol Shin of KAIST Graduate School of Medical Science and Engineering; and Dr. Je-kyung Seong, Director of Korea Mouse Phenotyping Center (KMPC).